Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
2
Table of Contents
1
Q3 & 9M FY-22
HIGHLIGHTS
2
BUSINESS OVERVIEW
3CAPABILITIES
4 FINANCIALS
5
OUTLOOK
3
Q3 & 9M FY-22 HIGHLIGHTS
Management Speak
SUCHETH DAVULURI, VICE-CHAIRMAN & CEO
"The quarter gone past was impacted by a lower than anticipated revenue primarily due to the weak performance of the Prime business which was 20% lower than the quarterly average over the previous year. We have been impacted by customers' issues on the market-share and inventory front for two of our key products. Having said that we have had our highest ever quarterly revenues from the CMS division, and we see growing utilization of Unit-3 for both GDS & CMS businesses."
SAHARSH DAVULURI, VICE-CHAIRMAN & MD
"FY 22 has been a challenging year for us with volatility both on the revenue and cost fronts. While Q3 revenues have been impacted by the GDS business, the ongoing raw material and supply chain challenges have also tested our mettle. Given the circumstances and on-going investments for the future, profitability margins this quarter are not reflective of the businesses' potential. On the CMS front, we are seeing good traction in new opportunities even as we are focused on delivering the current projects which are exciting in terms of their potential"
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 01 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 February 2022 10:01:00 UTC.
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
NEULAND LABORATORIES LIMITED 
